Dehydroepiandrosterone (DHEA) effects on HIV replication and host immunity: A randomized placebo-controlled study

AIDS Research and Human Retroviruses

Volumn 23, Issue 1, 2007, Pages 77-85

  Abrams, Donald I ^a,b   Shade, Starley B ^a,b   Couey, Paul ^a,b   Mccune, Joseph M ^b,c   Lo, Joan ^b,c   Bacchetti, Peter ^a   Chang, Barbara ^c   Epling, Lorrie ^a   Liegler, Teri ^c   Grant, Robert M ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; IMMUNOMODULATING AGENT; PLACEBO; PRASTERONE; PRASTERONE SULFATE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BODY COMPOSITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; VIRUS REPLICATION;

EID: 33846840940     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0170     Document Type: Article

References (30)

1. Finzi D, Hermankova M, Pierson T, Carruth LM, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
2. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-1295.
3. Grant RM, Abrams DI: All is not dead in HIV-1 graveyard. Lancet 1998;351:308-309.
4. Van Vollenhoven RF: Dehydroepiandrosterone: Uses and abuses. In: Textbook of Rheumatology (Kelley WN, Harris ED, Ruddy S, and Sledge CB, eds). Update 25, pp. 1-9. W.B. Saunders Co., New York, 1997.
5. Baulieu EE: Dehydroepiandrosterone (DHEA): A fountain of youth? J Clin Endocrinol Metab 1996;81:3147-3151.
6. May M, Holmes E, Rogers W, and Poth M: Protection from glucocorticoid induced thymic involution by dehydroepiandrosterone. Life Sci 1990;46:1627-1631.
7. Khorram O, Vu L, and Yen SSC: Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men. J Gerontol Med Sci 1997;52A:M1-M7.
8. Nestler JE, Barlascini CO, Clore JN, and Blackard WG: Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 1988;68:57-61.
9. Morales AJ, Haubrich RH, Hwang JY, Asakura H, and Yen SSC: The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol 1998;49:421-432.
10. Henderson E, Yang JY, and Schwartz A: Dehydroepiandrosterone (DHEA) and synthetic DHEA analogs are modest inhibitors of HIV-1 IIIB replication. AIDS Res Hum Retroviruses 1992;8:625-631.
11. Umar S, Feleke G, Roginsky MS, and Schaffer P: Effect of dehydroepiandrosterone (DHEA) on clinical and laboratory parameters in female patients with AIDS (FPWA). Proceedings of the 12th World Conference on AIDS, Geneva, 28 June-3 July, 1998 (abstract #42373).
12. Yang YL, Schwartz A, and Henderson EE: Inhibition of HIV-1 latency reactivation by dehydroepiandrosterone (DHEA) and an analog of DHEA. AIDS Res Hum Retroviruses 1993;9(8):747-754.
13. Havlir D, Bassett R, Levitan D, Gilbert P, Tebas P, Collier A, Hirsch M, Ignacio C, Condra J, Günthard H, Richman D, and Wong J: Prevalence and predictive value of intermittent viremia with combination therapy. JAMA 2001;286(2):171-179.
14. Maecker HT, Dunn HS, Suni MA, Khatamsas E, Pitcher CJ, Bunde T, Persaud N, Trigona W, Fu T-M, Sinclair E, Bredt BM, McCune JM, Maino VC, Kern F, and Picker LJ: Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 2001;255:27-40.
15. Berry SH, Bozzette SA, Hayes RD, Stewart A, and Kanouse DE: Measuring patient reported health status and experience in advanced HIV disease: The HIV-PARSE survey instrument. RAND Corp., Santa Monica, CA, 1994.
16. Wu AW, Rubin HR, Matthews WC, Ware JEJ, Brysk LT, Hardy WD, Bozzette SA, Spector SA, and Richman DD: A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care 1991;29:786-798.
17. McNair DM, Lorr M, and Droppleman LF: EdITS Manual for the Profile of Mood States. Educational and Industrial Testing Service, San Diego, CA, 1971.
18. Arlt W, Callies F, Koehler I, van Vlijmen JC, Fassnach M, Strasburger CJ, et al.: Dehydroepiandrosterone supplementation in healthy men with an age-related decline in dehydroepiandrosterone secretion. J Clin Endocrinol Metab 2001;86:4686-4692.
19. Jedrzejuk D, Medras M, Milewicz A, and Demissie M: Dehydroepiandrosterone replacement in healthy men with age-related decline of DHEA-S: Effects on fat redistribution, insulin sensitivity and lipid metabolism. Aging Male 2003;6:151-156.
20. Villareal DT and Holloszy JO: Effect of DHEA on abdominal fat and insulin action in elderly women and men: A randomized controlled trial. JAMA 2004;292:2243-2248.
21. Schambelan M, Benson CA, Carr A, Currier JS, Dube MP, Gerber JG, Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K, Powderly WG, Saag MS; International AIDS Society-USA: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002;31:257-75.
22. Grinspoon S and Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352:48-62.
23. Mondy K and Tebas P: Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis 2003;36(Suppl. 2):S101-105.
24. Thomas J and Doherty SM: HIV infection - a risk factor for osteoporosis. J Acquir Immune Defic Syndr 2003;33:281-291.
25. Gordon CM, Grace E, Emans SJ, Feldman HA, Goodman E, , Becker KA, Rosen CJ, Grundberg CM, and LeBoff MS: Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. J Clin Endocrinol Metab 2002;87:4935-4941.
26. Dyner TS, Lang W, Gaega J, Golub A, Stites D, Winger E, Galmarini M, Masterson J, and Jacobson MA: An open-label dose-escalation trial of oral dehydroepiandrosterone tolerance and pharmacokinetics in patients with HIV disease. J Acquir Immune Defic Syndr 1993;6:459-465.
27. Parasrampuria J, Schwartz K, and Petesch R: Quality control of dehydroepiandrosterone dietary supplement products. JAMA 1998;280:1565.
28. Kornblut AE and Wilson D: How one pill escaped place on steroid list. New York Times, April 17, 2005.
29. Hunt PJ, Gurnell EM, Huppert FA, Richards C, Prevost AT, Wass JA, Herbert J, and Chatterjee VK: Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addisons's disease in a randomized, double blind trial. J Clin Endocrinol Metab 2000;85:4650-4656.
30. Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L, and Roberts E: Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999;56:646-649.